FINNENCE ▪ THE WIRE FILE
THE WIRE · № 79708
News■ Unclear/unknown
ROMTech Wins Newsweek 2026 AI Impact Health Award for AI-Enabled Remote Patient Monitoring
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
An award for a private rehab-tech vendor gives no revenue or adoption data for public medtech.
Private medtech PR; no investable read-through
CATALYST TO WATCH
None stated in the release
MAIN RISK
Extrapolating remote-monitoring demand from an award
FULL DISPATCH
BROOKFIELD, Conn., Oct. 14, 2026 /PRNewswire/ -- ROM Technologies Inc.® (ROMTech®), creator of the PortableConnect® platform and a national leader in intelligent rehabilitation technology, announced today it has been named the winner of the "AI Impact – Remote Patient Monitoring" category...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDAI
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
NYC & Global Walk - 2026 FINAL Walk with Us to Cure Lupus Returns to New York City and Around the World on October 242026-10-14 12:28 UTC
NYC & Global Walk - 2026 FINAL Walk with Us to Cure Lupus Returns to New York City and Around the World on October 242026-10-14 12:28 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis — Almirall, S.A.2026-10-14 12:00 UTC
New Phase 3 trial: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis — Almirall, S.A.2026-10-14 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome — Hoffmann-La Roche2026-10-14 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome — Hoffmann-La Roche2026-10-14 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc2026-10-14 12:00 UTC
Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc2026-10-14 12:00 UTC
→CORRELATIONshares AI
IPO News - IPO Weekly Weigh-in: Why investors said no to this $3.5B AI IPO2026-10-14 12:41 UTC
IPO News - IPO Weekly Weigh-in: Why investors said no to this $3.5B AI IPO2026-10-14 12:41 UTC
→CORRELATIONshares AI
Omega Point's MCP Is Now Anthropic Verified in Claude's Marketplace, Built To Compute2026-10-14 12:52 UTC
Omega Point's MCP Is Now Anthropic Verified in Claude's Marketplace, Built To Compute2026-10-14 12:52 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.